The most recent European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines also provide both secondary non-HDL-C and apoB targets, and state that apoB may be the preferred test in patients with hypertriglyceridemia [18]. The gene discussed is APOB; the disease is hypertriglyceridemia.